The attributable cost of catheter‐associated urinary tract infections in the United States: A systematic review
Abstract
HighlightsA systematic review of the literature identified only 4 studies that produced original estimates of the attributable cost of catheter‐associated urinary tract infections (CAUTIs) in the United States since the year 2000.In 2016 U.S. dollars, the reported attributable costs of CAUTIs are $876 (inpatient costs to the hospital for additional diagnostic tests and medications); $1,764 (inpatient costs to Medicare for non‐intensve care unit [ICU] patients); $7,670 (inpatient and outpatient costs to Medicare); $8,398 (inpatient costs to the hospital for pediatric patients); and $10,197 (inpatient costs to Medicare for ICU patients).The prevailing notion of a CAUTI costing approximately $1,000 is an underestimate and an oversimplification of its true economic burden, because many factors such as patient population, patient acuity, infection etiology, and cost perspective can increase the cost well above $1,000.Additional research is needed to accurately assess the full economic effect that CAUTIs have on hospitals and on the U.S. healthcare system. Background: Catheter‐associated urinary tract infections (CAUTIs) are the most common healthcare‐acquired condition. The attributable cost of CAUTIs is frequently cited to be approximately $1,000. However, there is a paucity of recent literature that confirms this estimate. The purpose of this study was to perform a systematic review of the literature that estimates the attributable cost of CAUTIs in the United States. Methods:…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.